Predicted Risks of Cardiovascular Disease Following Chemotherapy and Radiotherapy in the UK NCRI RAPID Trial of Positron Emission Tomography-Directed Therapy for Early-Stage Hodgkin Lymphoma.
David J CutterJohanna RamrothPatricia DiezAndy BuckleGeorgios NtentasBilyana PopovaLaura Clifton-HadleyPeter J HoskinSarah C DarbyJohn RadfordTimothy M IllidgePublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
Predicted excess cardiovascular risk is small for most patients, so radiotherapy may provide net benefit. However, for a minority of patients receiving high doses of radiation to cardiovascular structures, it may be preferable to consider advanced radiotherapy techniques to reduce doses or to omit radiotherapy and accept the increased relapse risk. Individual assessment of cardiovascular and other risks before treatment would allow personalized decision making about radiotherapy in ES-HL.
Keyphrases
- early stage
- locally advanced
- positron emission tomography
- radiation induced
- hodgkin lymphoma
- cardiovascular disease
- radiation therapy
- computed tomography
- end stage renal disease
- decision making
- rectal cancer
- sentinel lymph node
- neoadjuvant chemotherapy
- squamous cell carcinoma
- type diabetes
- high resolution
- metabolic syndrome
- ejection fraction
- clinical trial
- newly diagnosed
- chronic kidney disease
- coronary artery disease
- pet ct
- cross sectional
- phase iii
- pet imaging
- mass spectrometry
- patient reported
- cardiovascular risk factors
- replacement therapy